High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme

P Kadiyala, D Li, FM Nuñez, D Altshuler, R Doherty… - ACS …, 2019 - ACS Publications
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor, for which there is no
cure. Treatment effectiveness for GBM has been limited due to tumor heterogeneity, an …

[HTML][HTML] Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice

P Kadiyala, SV Carney, JC Gauss… - The Journal of …, 2021 - Am Soc Clin Investig
Mutant isocitrate dehydrogenase 1 (IDH1-R132H; mIDH1) is a hallmark of adult gliomas.
Lower grade mIDH1 gliomas are classified into 2 molecular subgroups: 1p/19q codeletion/…

Systemic delivery of an adjuvant CXCR4–CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy

…, AV Andjelkovic, JV Gregory, P Kadiyala… - ACS …, 2022 - ACS Publications
Glioblastoma (GBM) is an aggressive primary brain cancer, with a 5 year survival of ∼5%.
Challenges that hamper GBM therapeutic efficacy include (i) tumor heterogeneity, (ii) …

[HTML][HTML] Immunosuppressive myeloid cells' blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy

N Kamran, P Kadiyala, M Saxena, M Candolfi, Y Li… - Molecular Therapy, 2017 - cell.com
Survival of glioma (GBM) patients treated with the current standard of care remains dismal.
Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host …

IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response

FJ Núñez, FM Mendez, P Kadiyala… - Science translational …, 2019 - science.org
Patients with glioma whose tumors carry a mutation in isocitrate dehydrogenase 1 (IDH1
R132H ) are younger at diagnosis and live longer. IDH1 mutations co-occur with other …

[HTML][HTML] Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy

JV Gregory, P Kadiyala, R Doherty, M Cadena… - Nature …, 2020 - nature.com
Glioblastoma (GBM), the most aggressive form of brain cancer, has witnessed very little
clinical progress over the last decades, in part, due to the absence of effective drug delivery …

Matrix metalloproteinase activity in infections by an encephalitic virus, mouse adenovirus type 1

SL Ashley, CD Pretto, MT Stier, P Kadiyala… - Journal of …, 2017 - Am Soc Microbiol
Mouse adenovirus type 1 (MAV-1) infection causes encephalitis in susceptible strains of
mice and alters the permeability of infected brains to small molecules, which indicates …

Prospects of biological and synthetic pharmacotherapies for glioblastoma

DB Altshuler, P Kadiyala, FJ Nuñez… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: The field of neuro-oncology has experienced significant advances in recent
years. More is known now about the molecular and genetic characteristics of glioma than ever …

Arginase 1 is a key driver of immune suppression in pancreatic cancer

…, W Yan, F Lima, A Bischoff, P Kadiyala… - Elife, 2023 - elifesciences.org
An extensive fibroinflammatory stroma rich in macrophages is a hallmark of pancreatic
cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and …

WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer

W Du, RE Menjivar, KL Donahue, P Kadiyala… - Journal of Experimental …, 2022 - rupress.org
Pancreatic ductal adenocarcinoma (PDA) is associated with activation of WNT signaling.
Whether this signaling pathway regulates the tumor microenvironment has remained …